KDR and neoplasm: The intention of this drug regimen is to disrupt paracrine substitutional signaling within the tumorigenic network in order to prevent adaptive drug resistances: The tumor-promoting effects of endothelial cells, (i) angiogenesis, (ii) tumor cell survival, and (iii) metastasis, are targeted by inhibition of the VEGF-VEGFR2 axis with cabozantinib.